Connect your AI

Relmada Therapeutics, Inc. RLMD Q4 2024 Annual earnings

Reported March 27, 2025 · After market close

Diluted EPS-$0.62Beat by $0.08

EPS estimate-$0.70

Next report

Aug 6, 2026 (In 3 weeks)

EPS estimate-$0.21

Financials

Q4 2024

Income statement

Operating income-$19.1M+28.9%

Net income-$18.7M+25.9%

EPS (diluted)-$0.62+25.3%

Balance sheet

Cash & equivalents$3.9M-5.7%

Total equity$35.5M-58.4%

Total assets$45.8M-53.0%

Cash flow

Operating cash flow-$8.8M+14.1%

Valuation & ratios

Valuation

as of 12/31/24

Market cap$15.69M-87.4%

Returns & leverage

Return on equity-132.3%+139pp

Current ratio4.4×-3.5×

Versus estimates

Diluted EPS

Q1 2026-$0.22Miss by $0.04 Q4 2025-$0.27Miss by $0.13 Q3 2025-$0.30Miss by $0.26 Q2 2025-$0.30Miss by $0.05 Q1 2025-$0.58Miss by $0.27

Q4 2024-$0.62Beat by $0.08

Ask the moment Relmada Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did Relmada Therapeutics, Inc. report Q4 2024 earnings?: Relmada Therapeutics, Inc. (RLMD) reported Q4 2024 earnings on March 27, 2025 after market close.
What were Relmada Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Relmada Therapeutics, Inc. reported diluted EPS of $-0.62 for Q4 2024.
Did Relmada Therapeutics, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.70 by $0.08.
Where can I find Relmada Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001013762-25-003426) directly on SEC EDGAR. The filing index links above go to sec.gov.